CAPTRUST Financial Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

CAPTRUST Financial Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.21M	Buy	19,945 +1,798	+10%	+$163K	﹤0.01%	1247
2026 Q1	$1.58M	Sell	18,147 -178	-1%	-$17.3K	﹤0.01%	1331
2025 Q4	$1.96M	Buy	18,325 +67	+0.4%	+$7.11K	﹤0.01%	1108
2025 Q3	$1.84M	Buy	18,258 +787	+5%	+$73.1K	﹤0.01%	1068
2025 Q2	$1.1M	Buy	17,471 +114	+0.7%	+$6.98K	﹤0.01%	1303
2025 Q1	$919K	Buy	+17,357	New	+$963K	﹤0.01%	1324
2021 Q4	–	Sell	-19	Closed	–	–	4891
2021 Q3	$0	Sell	19 -12	-39%	-$183	﹤0.01%	4741
2021 Q2	$1K	Hold	31	–	–	﹤0.01%	4377
2021 Q1	$1K	Buy	+31	New	+$899	﹤0.01%	4231

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAPTRUST Financial Advisors's RYTM Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Rhythm Pharmaceuticals (RYTM) stake by 9.9% in Q2 2026, buying an estimated $163K and bringing the position to 19,945 shares worth $2.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1247.

CAPTRUST Financial Advisors first reported a position in RYTM in Q1 2021 and has held it in 9 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

CAPTRUST Financial Advisors held 19,945 shares of Rhythm Pharmaceuticals worth $2.21M as of Q2 2026.
CAPTRUST Financial Advisors bought 1,798 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $163K.
Rhythm Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #1247 holding.
CAPTRUST Financial Advisors first reported a position in Rhythm Pharmaceuticals in Q1 2021 and has held it in 9 quarters since.
304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.